Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran

Abstract Background Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD). The combination of rivaroxaban with aspirin imposes a synergistic effect on the inhibition o...

Full description

Bibliographic Details
Main Authors: Zahra Goudarzi, Zhila Najafpour, Ahmad Gholami, Khosro Keshavarz, Mohammad Mahdi Mojahedian, Mohammad Mehdi Babayi
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Health Services Research
Subjects:
Cost-effectiveness
Cost-utility
CAD
PAD
Rivaroxaban
Aspirin
Online Access:https://doi.org/10.1186/s12913-025-12431-3

Internet

https://doi.org/10.1186/s12913-025-12431-3

Similar Items